These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32920151)

  • 1. Veverimer: An Emerging Potential Treatment Option for Managing the Metabolic Acidosis of CKD.
    Adrogué HJ; Madias NE
    Am J Kidney Dis; 2020 Dec; 76(6):861-867. PubMed ID: 32920151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
    Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
    J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Aug; 394(10196):396-406. PubMed ID: 31248662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
    Mathur VS; Li E; Wesson DE
    Nephrol Dial Transplant; 2022 Jun; 37(7):1302-1309. PubMed ID: 34240198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
    Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA
    J Am Soc Nephrol; 2024 Mar; 35(3):311-320. PubMed ID: 38261535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in management of chronic metabolic acidosis in chronic kidney disease.
    Chen W; Abramowitz MK
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):409-416. PubMed ID: 31232712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
    Mathur VS; Wesson DE; Tangri N; Li E; Bushinsky DA
    BMC Nephrol; 2022 Feb; 23(1):82. PubMed ID: 35216581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
    Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
    Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
    Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Potential for Veverimer Drug-Drug Interactions.
    Parsell D; Shao J; Guttendorf R; Mathur V; Li E; Wu YS; Tsao L; Tabakman S; Stasiv Y; Lee A; Biyani K; Klaerner G
    Drug Metab Dispos; 2021 Jul; 49(7):490-500. PubMed ID: 34031138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Acidosis in Patients with CKD: Epidemiology, Pathogenesis, and Treatment.
    Adamczak M; Surma S
    Kidney Dis (Basel); 2021 Nov; 7(6):452-467. PubMed ID: 34901192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Metabolic Acidosis in Chronic Kidney Disease.
    Patschan D; Patschan S; Ritter O
    Kidney Blood Press Res; 2020; 45(6):812-822. PubMed ID: 33264780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Veverimer in the Treatment of Metabolic Acidosis Caused by Chronic Kidney Disease: A Meta-analysis.
    Liu W; Li L; Zhang X; Dong H; Lu M
    Front Pharmacol; 2021; 12():643128. PubMed ID: 33995050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance to Sodium in Patients With CKD-Induced Metabolic Acidosis: Does the Accompanying Anion Matter?
    Bushinsky DA
    Am J Kidney Dis; 2019 Jun; 73(6):858-865. PubMed ID: 30518477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing metabolic acidosis in chronic kidney disease: importance of blood pH and serum anion gap.
    Kaimori JY; Sakaguchi Y; Kajimoto S; Asahina Y; Oka T; Hattori K; Doi Y; Isaka Y
    Kidney Res Clin Pract; 2022 May; 41(3):288-297. PubMed ID: 35172536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Metabolic Acidosis in Chronic Kidney Disease: Past, Present, and Future Direction.
    Goraya N; Narayanan M; Wesson DE
    Adv Chronic Kidney Dis; 2022 Jul; 29(4):416-423. PubMed ID: 36175079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic acidosis in chronic kidney disease].
    Havlín J; Matoušovic K; Vaňková S; Schück O
    Vnitr Lek; 2016; 62 Suppl 6():30-39. PubMed ID: 28124929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A basic solution for a complex problem: does treatment of metabolic acidosis slow CKD progression?
    Bodker K; Freidin N; Arora N
    Curr Opin Nephrol Hypertens; 2024 May; 33(3):304-310. PubMed ID: 38420899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fruit and Vegetable Treatment of Chronic Kidney Disease-Related Metabolic Acidosis Reduces Cardiovascular Risk Better than Sodium Bicarbonate.
    Goraya N; Munoz-Maldonado Y; Simoni J; Wesson DE
    Am J Nephrol; 2019; 49(6):438-448. PubMed ID: 30995657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.